Pfizer Inc may file for emergency-use authorization of the corona vaccine by the November end if it produces the desired result from ongoing Phase 3 clinical trials. This is the first time when the Western vaccine developer has provided a specific deadline to roll out the coronavirus vaccine. The vaccine candidate, BNT162b2, is related to BioNTech’ s proprietary mRNA technology and assisted by Pfizer’s global vaccine development and manufacturing powers.
